367 related articles for article (PubMed ID: 18298593)
21. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
[TBL] [Abstract][Full Text] [Related]
22. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
[TBL] [Abstract][Full Text] [Related]
23. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
[TBL] [Abstract][Full Text] [Related]
24. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
[TBL] [Abstract][Full Text] [Related]
25. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions.
Blumberg N; Gettings KF; Turner C; Heal JM; Phipps RP
Transfusion; 2006 Oct; 46(10):1813-21. PubMed ID: 17002639
[TBL] [Abstract][Full Text] [Related]
26. Platelet function in variable platelet split products intended for neonatal transfusion.
Strasser EF; Stachel DK; Schwarzkopf P; Ringwald J; Weisbach V; Zimmermann R; Zingsem J; Eckstein R
Transfusion; 2006 May; 46(5):757-65. PubMed ID: 16686843
[TBL] [Abstract][Full Text] [Related]
27. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.
Lin L; Conlan MG; Tessman J; Cimino G; Porter S
Transfusion; 2005 Oct; 45(10):1610-20. PubMed ID: 16181212
[TBL] [Abstract][Full Text] [Related]
28. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method.
Sandgren P; Tolksdorf F; Struff WG; Gulliksson H
Vox Sang; 2011 Jul; 101(1):35-43. PubMed ID: 21175668
[TBL] [Abstract][Full Text] [Related]
29. Effect of extending the platelet storage time on platelet utilization: predictions from a mathematical model of prophylactic platelet support.
Pereira A; Sanz C
Transfus Med; 2007 Apr; 17(2):119-27. PubMed ID: 17430468
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution.
Johnson L; Winter KM; Hartkopf-Theis T; Reid S; Kwok M; Marks DC
Transfusion; 2012 Mar; 52(3):503-9. PubMed ID: 21880041
[TBL] [Abstract][Full Text] [Related]
32. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
33. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers.
Seghatchian J
Transfus Apher Sci; 2006 Feb; 34(1):125-30. PubMed ID: 16376152
[TBL] [Abstract][Full Text] [Related]
34. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
35. Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage.
Glenister KM; Payne KA; Sparrow RL
Transfusion; 2008 Jan; 48(1):99-107. PubMed ID: 17894789
[TBL] [Abstract][Full Text] [Related]
36. The effect of gamma irradiation on the quality of apheresis platelets during storage for 7 days.
Tynngård N; Studer M; Lindahl TL; Trinks M; Berlin G
Transfusion; 2008 Aug; 48(8):1669-75. PubMed ID: 18482187
[TBL] [Abstract][Full Text] [Related]
37. Interruption of agitation of platelet concentrates: a multicenter in vitro study by the BEST Collaborative on the effects of shipping platelets.
Dumont LJ; Gulliksson H; van der Meer PF; Murphy S; Nixon JG; de Wildt-Eggen J; Vandenbroeke T; Aubuchon JP
Transfusion; 2007 Sep; 47(9):1666-73. PubMed ID: 17725732
[TBL] [Abstract][Full Text] [Related]
38. A rest period before agitation may improve some in vitro apheresis platelet parameters during storage.
Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Wagner SJ
Transfusion; 2012 Jul; 52(7):1433-8. PubMed ID: 22211457
[TBL] [Abstract][Full Text] [Related]
39. Soluble glycoprotein V as a quality marker of platelet concentrates stressed by transportation.
Javela K; Eronen J; Sarna S; Kekomäki R
Transfusion; 2005 Sep; 45(9):1504-11. PubMed ID: 16131384
[TBL] [Abstract][Full Text] [Related]
40. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates.
Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ
Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
